摘要
目的探讨丁二酸洛沙平与利培酮治疗精神分裂症的疗效与安全性,为治疗精神分裂症积累经验。方法将62例精神分裂症患者,随机分为丁二酸洛沙平组31例,利培酮组31例,分别给予丁二酸洛沙平和利培酮治疗,疗程8周。在治疗前及治疗2、4、8周末,采用阳性与阴性症状量表(PANSS)和治疗中出现的症状量表(TESS)分别评定临床疗效和不良反应。结果丁二酸洛沙平组显效率77.42%,利培酮组为80.64%,2组比较差异无显著性(P(0.05),丁二酸洛沙平组睡眠障碍发生率明显少于利培酮组(P<0.05)。结论丁二酸洛沙平治疗精神分裂症具有起效快、疗效好,安全性高。
Objective To explore the efficacy and safety of loxapine succinate and resperidone in treatment of patients with schizophrenia,so as to accumulate experiences for treating schizophrenia.Methods 62 patients with schizophrenia were randomly divided into a loxapine succinate group （n=31） and a resperidone group （n=31） for the treatment of 8 weeks.The efficacy and side effects were evaluated by Positive and Negative Symptom Scale （PANSS） and Treatment Emergent Symptoms Scale （TESS）before and after 2,4 and 8 treatmeat weeks.Results The effective rates of loxapine succinate and resperidone were 77.42% and 80.64% respectively,which showed no significant difference（P﹥0.05）.The incidence of sleep disorders of the loxapine succinate group was lower than that of the resperidone group（P〈0.05）. Conclusion Loxapine succinate is an effective drug for schizophrenia,with rapid efficacy and few side effects.
出处
《淮海医药》
CAS
2010年第3期203-204,共2页
Journal of Huaihai Medicine
